Opinion|Videos|July 10, 2024
ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management
Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the data presented at ASCO 2024 on the RELATIVITY-047 study of nivolumab plus relatlimab vs nivolumab in patients with previously untreated metastatic or unresectable melanoma.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Please provide your key takeaways from this study.
- How might these findings impact the management of patients with metastatic melanoma?
- The study examined melanoma-specific survival (MSS) outcomes. What is the significance of sustained improvement in MSS observed with nivolumab plus relatlimab?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies
2
FDA Approves Another OTC Naloxone Nasal Spray for Opioid Overdose
3
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
4
United Therapeutics Plans FDA Submission for Inhaled Treprostinil in IPF
5